Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings
Crossref DOI link: https://doi.org/10.1007/s40261-017-0506-3
Published Online: 2017-02-17
Published Print: 2017-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Keyserling, Constance H.
Barbaras, Ronald
Benghozi, Renee
Dasseux, Jean-Louis
Funding for this research was provided by:
Cerenis Therapeutics
License valid from 2017-02-17